Price sinking, but no news ? |
Tnt99, you've been wrong on every price prediction and post you've made for the last 3 or so years I've been following this blog and this stock. Either provide proof or just stop. |
No news. Insider info? |
Well it seems that an approach has been made!!! |
What's happened? |
And so it starts!! |
Could also be the money spent on purchase of the head office makes sense to me And shows me they are in it for the long haul |
Product development may explain the cash reduction of $2.4M.
Any idea what new products are due?
"Our plans include adding new products which will further diversify our product offering and will be implemented to drive further growth in 2025."
GMB-V separated out makes sense.
Someone has been happy to take sales at 58p.
Surprised it didn't fall back further. |
Not sure why my sale at 15.26 is not showing on the ADVFN trades?
Edit now showing as trade 62 between trades 57 and 58! |
I have some concerns over the cash burn. The cash at Dec 23 was $4.7m (although in the trading update it suggest it was $4.3m, which presumably is because the difference is being attributed to the GBM-V assets now for sale).
Taking the lower figure of $4.3m and the forecast closing cash of $1.9m suggests the cash used during the year was $2.4m which means depending on how much it reduces over the following year they may not have enough cash for the next 12 mths. Having said that, they have mentioned they have an additional $4m of the revolving credit they can use.
However, out of caution I have decided to sell most of my holding leaving a small amount to run and will wait to see what the position is when the results for the year are released. |
Hopefully we will get that in the next full detailed review |
Informative update, adding more clarity on EBITDA, cash flow, and the strategic review timeline would help. |
One concern is what may happen to the price if there are no firm offers or interests.
The RULE 2.4 announcement from 4th November 2024 has no maximum duration before needing to be closed (it has now been 2.5 months) but further market updates should be made.
Surely TRX should update the market soon? Three months having passed on 4th Feb 2025?
"A Rule 2.4 announcement triggered by media speculation can remain open as long as the company continues to monitor the situation and ensure compliance with its obligations under the Takeover Code and the UK Listing Rules. However, the company is expected to provide a closure announcement within a reasonable timeframe if no acquirer is identified or no interest materializes. While there is no strict maximum duration, this timeframe typically does not exceed a few months without further updates or action." |
 If there is no offer made does anyone think TRX might try to raise more cash to help scale and increase market reach?
Integra have a had a bit of a hard time but appear to be turning a corner and new CEO started about now. They have made 15 tissue related acquisitions since Oct 2002.
Stryker appear to have made only 2 or 3.
A report being touted around, Healthcare Industry News:
"The tissue engineering landscape is experiencing an extraordinary surge, with projections indicating a remarkable leap from USD 4.4 billion in 2023 to an impressive USD 8.9 billion by 2028. This represents a robust Compound Annual Growth Rate (CAGR) of 15.3%.
Key Highlights:
- Current Market Value: USD 4.4 billion (2023)
- Projected Market Value: USD 8.9 billion (2028)
- Growth Rate: 15.3% CAGR
What's driving this exponential growth?
- Breakthrough regenerative medicine technologies
- Increasing chronic disease prevalence
- Rising demand for personalized healthcare solutions
- Advances in stem cell research and bioengineering
𝐓𝐡𝐞 𝐜𝐨𝐦𝐩 9834;𝐧Ү42;𝐞𝐬; 𝐟𝐞𝐚𝐭 9854;𝐫Ү38;𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨 9851;𝐭 𝐢𝐧𝐜𝐥 9854;𝐝Ү38;:
Organogenesis, AbbVie, Baxter International Inc., BD, B. Braun Group, Teijin Limited, Institut Straumann AG, Integra LifeSciences, Johnson & Johnson, Medtronic, NuVasive, Stryker, Terumo Medical Corporation, W. L. Gore & Associates, Zimmer Biomet, Smith+Nephew, MiMedx, BioTissue, CollPlant, Sumitomo Pharma America, Inc., Matricelf, Mallinckrodt Pharmaceuticals, REGROW BIOSCIENCES, Vericel® Corporation, TECNOSS S.R.L., Tegoscience (South Korea), and Tissue Regenix Group
Other Companies that are Operating in this Market Globally:
Integra LifeSciences
Aesthetics Biomedical® Inc
Regenity Biosciences
Acelity
ACell, Inc.
Sofwave
Scapa Healthcare
Gentell
GT Medical Technologies, Inc.
Osteogenics Biomedical, Inc.
SYMATESE
EndyMed Medical
Regenity Biosciences (Formerly Polyganics)
RESORBA Medical (Advanced Medical Solutions)" |
One concern is the piddling size of TRX vs potential acquirers. TRX unlikely to move the needle for them. |
Re Lexham, I meant to add that the second lot of shares acquired by Lexham also appear to have come from IPGroup [IPO] rather than the market. |
What sort of premium over todays price would people expect?
Looking over others that could carry TRX in that market it comes down to a few: Stryker, Integra LifeSciences, Medtronic, Smith & Nephew, Zimmer Biomet.
Smith & Nephew, Zimmer-B look unlikely to me. So that leaves Stryker, Medtronic, Integra Life Sciences.
Of those 3, Stryker & Integra would be my guesses. |
For info Lexham recently bought a load of TRX direct from IP Group, along with some other shares. They were prior to this announcement just under the UK reporting threshold of 3%. |
lexham invests c 5pc good one surely |
Bid approach in the new year ??!!! |
They might just be working out who to get on side to make sure any deal goes through and what expectations are. |
Presumably the management are impatient with the share price. They have repositioned the company, increased the supply chain and revenue, but the share price has hardly moved for years now. They could always move the listing to the US, but a sale would seem like a reasonable option, although, we're not going to vote in favour without a decent premium imo |
PJ84, I don't have email access during the day [no signal!], but can try later.
I'll have a think how to angle it. I am almost certain that if they replied, I would not be allowed to share the info. I wonder if another route might be possible, via email to Research Tree or direct to significant investors in TRX? |
bamboo2 TRX can and obviously have accessed the article they referred you to.
Just checked the Betaville subscription rate and £5,000/qtr. (non-refundable is a bit steep for private investors)
Maybe a polite follow up email might elicit a bit more information from TRX? |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
